PRNewswire (Thu, 9-Jul 5:40 PM ET)
Certara Accelerates Drug Discovery and Development with NVIDIA BioNeMo Agent Toolkit
Globe Newswire (Tue, 7-Jul 8:00 AM ET)
PRNewswire (Mon, 6-Jul 8:55 AM ET)
PRNewswire (Mon, 6-Jul 8:45 AM ET)
Globe Newswire (Fri, 19-Jun 2:11 PM ET)
Globe Newswire (Thu, 18-Jun 7:15 PM ET)
Certara Faces CFO Transition but Reaffirms 2026 Guidance Amid Leadership Change
Market Chameleon (Thu, 18-Jun 5:21 AM ET)
Certara Announces CFO Transition
Globe Newswire (Wed, 17-Jun 4:30 PM ET)
The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath It
PRNewswire (Tue, 16-Jun 8:45 AM ET)
CERT Investors Have Opportunity to Join Certara, Inc. Fraud Investigation with the Schall Law Firm
PRNewswire (Mon, 8-Jun 12:02 PM ET)
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.
Certara trades on the NASDAQ stock market under the symbol CERT.
As of July 14, 2026, CERT stock price declined to $6.66 with 398,538 million shares trading.
CERT has a beta of 2.64, meaning it tends to be more sensitive to market movements. CERT has a correlation of 0.20 to the broad based SPY ETF.
CERT has a market cap of $1.04 billion. This is considered a Small Cap stock.
Last quarter Certara reported $107 million in Revenue and $.09 earnings per share. This beat revenue expectation by $894,000 and missed earnings estimates by -$.01.
In the last 3 years, CERT traded as high as $19.87 and as low as $4.45.
The top ETF exchange traded funds that CERT belongs to (by Net Assets): IJR, VTI, IWM, VB, VXF.
CERT has underperformed the market in the last year with a return of -39.9%, while SPY returned +21.9%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in CERT shares. However, CERT has outperformed the market in the last 3 month and 2 week periods, returning +15.0% and +4.7%, while SPY returned +10.0% and +1.6%, respectively. This indicates CERT has been having a stronger performance recently.
CERT support price is $6.48 and resistance is $7.10 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CERT shares will trade within this expected range on the day.
